Literature DB >> 10622221

On the inotropic actions of arginine vasopressin in ventricular muscle of the guinea pig heart.

S Fujisawa1, T Iijima.   

Abstract

Arginine vasopressin (AVP) (0.03-3 microM) produced transient negative responses that were followed by slowly developing positive inotropic responses in guinea pig papillary muscles. The inotropic responses were antagonized by OPC-21268 (10 microM), but not by OPC-31260, and suppressed by neomycin (3 mM). The negative inotropic response was hardly affected by staurosporine (10 nM) and H-7 (10 microM). AVP (1 microM) elicited a transient decrease followed by a slowly developing increase in I(Ca). The latter increase in I(Ca) was not elicited in the presence of staurosporine (1 nM). These results indicate that AVP stimulates V1 receptors that couple to phosphoinositide hydrolysis and thereby increases intracellular Ca2+ and activates protein kinase C.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10622221     DOI: 10.1254/jjp.81.309

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  4 in total

Review 1.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Role of vasopressin in the management of septic shock.

Authors:  Gökhan M Mutlu; Phillip Factor
Journal:  Intensive Care Med       Date:  2004-04-21       Impact factor: 17.440

3.  Vasopressin in vasodilatory shock: is the heart in danger?

Authors:  Balázs Hauser; Pierre Asfar; Enrico Calzia; Régent Laporte; Michael Georgieff; Peter Radermacher
Journal:  Crit Care       Date:  2008-04-10       Impact factor: 9.097

4.  Vasopressin impairs brain, heart and kidney perfusion: an experimental study in pigs after transient myocardial ischemia.

Authors:  Stig Müller; Ole-Jakob How; Stig Eggen Hermansen; Thor Allan Stenberg; Georg Sager; Truls Myrmel
Journal:  Crit Care       Date:  2008-02-21       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.